Interleukin-8 and leukotriene-B(4), but not formylmethionyl leucylphenylalanine, stimulate CD18-independent migration of neutrophils across human pulmonary endothelial cells in vitro.
Although neutrophil migration from the systemic circulation involves the beta2- (or CD18) integrin family, the existence of an alternative, CD18-independent route of neutrophil extravasation to tissues has been demonstrated in animal models. The molecular interactions involved in this alternative migratory route have not yet been characterized. The objective of this study was to assess the CD18-dependency of neutrophil migration across human endothelial cells from an organ known to support CD18-independent migration, the lung, with a view to establishing an in vitro model to facilitate study of CD18-independent migration. Neutrophil migration across human pulmonary artery endothelial cells (HPAECs) in response to three different chemoattractants, formylmethionyl leucylphenyl-alanine (FMLP), interleukin (IL)-8, and leukotriene (LT) B(4), was examined. Results demonstrated that a function-blocking antibody to CD18 decreased FMLP-stimulated migration by 71.7 +/- 4.4% (P < 0.001). In contrast, migration in response to LTB(4) was decreased by only 20.5 +/- 10.2% (P < 0.01), and no significant decrease was observed with migration to IL-8. Neutrophils that migrated to FMLP had 1.7-fold more surface CD11b/CD18 compared with nonmigrated neutrophils (P < 0.01), whereas this integrin complex was not significantly upregulated on neutrophils that had migrated to IL-8 or LTB(4). Further investigation of this migratory route indicated that it did not involve the beta1 integrins (CD29) or the endothelial selectins, E- or P-selectin, nor did it require the activity of either metalloproteinases or neutrophil elastase. These results indicate that neutrophil migration across HPAECs in vitro to IL-8 and LTB(4) is predominantly CD18-independent and provides a much-needed in vitro system for examination of the neutrophil-endothelial interactions involved in this alternative migratory route.
Mackarel
A J
AJ
Department of Medicine and Therapeutics, University College Dublin, Ireland. ajmack@macollamh.ucd.ie
Russell
K J
KJ
Brady
C S
CS
FitzGerald
M X
MX
O'Connor
C M
CM
D018845:CD11 Antigens / Q000187:drug effects / Q000378:metabolism; D018821:CD18 Antigens / Q000502:physiology*; D002460:Cell Line; D002465:Cell Movement / Q000187:drug effects*; D002630:Chemotactic Factors / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004730:Endothelium, Vascular / Q000166:cytology / Q000187:drug effects*; D005998:Glycine / Q000031:analogs & derivatives / Q000494:pharmacology; D006801:Humans; D006877:Hydroxamic Acids; D016209:Interleukin-8 / Q000493:pharmacokinetics / Q000494:pharmacology*; D019041:L-Selectin / Q000187:drug effects / Q000378:metabolism; D007975:Leukotriene B4 / Q000493:pharmacokinetics / Q000494:pharmacology*; D008168:Lung / Q000098:blood supply; D009240:N-Formylmethionine Leucyl-Phenylalanine / Q000493:pharmacokinetics / Q000494:pharmacology; D009504:Neutrophils / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism; D010539:Permeability; D010649:Phenylalanine / Q000031:analogs & derivatives / Q000494:pharmacology; D011480:Protease Inhibitors / Q000494:pharmacology; D011719:Pyrazines; D013449:Sulfonamides / Q000494:pharmacology; D013876:Thiophenes / Q000494:pharmacology
D018845:CD11 Antigens; D018821:CD18 Antigens; C097658:CGS 27023A; D002630:Chemotactic Factors; D006877:Hydroxamic Acids; D016209:Interleukin-8; D011480:Protease Inhibitors; D011719:Pyrazines; D013449:Sulfonamides; D013876:Thiophenes; D019041:L-Selectin; D007975:Leukotriene B4; D010649:Phenylalanine; D009240:N-Formylmethionine Leucyl-Phenylalanine; C080985:batimastat; C069195:sivelestat; D005998:Glycine